Oncology Exchange
Frequently Asked Questions Regarding the Management of Multiple Myeloma in the Community Setting
Breast Cancer - Emerging Agents in Her2-postitive Breast Cancer
Emerging Strategies for the Management of Recurrent Ovarian Cancer
Non-Hodgkin's Lymphoma - Emerging Agents in Relapse/Refactory Non-Hodgkin's Lymphoma
Gastrointestinal Stromal Tumors - Emerging Multidisciplinary Approaches for the Management of Gastrointestinal Stromal Tumors
Challenges in Treating Renal Cell Carcinoma in the Community
Current Treatment Strategies for Chronic Myelogenous Leukemia
Personalizing Treatment for NSCLC An Oncology Exchange Program
Evidence-based Management of Metastatic Colorectal Cancer
Evolving Treatment Strategies for Mantle Cell Lymphoma in Elderly Patients
Emerging Strategies in Newly Diagnosed and Relapsed/Refractory Hodgkin Lymphoma
Rockpointe.com The confluence of medical science and clinical need

Oncology Exchange:
Emerging Strategies in Relapsed/Refractory Non-Hodgkin’s Lymphoma

A series of Live Grand Rounds Programs and an on-demand, CME-certified Webcourse

Welcome to "Oncology Exchange: Emerging Agents in Relapsed/Refractory Non-Hodgkin’s Lymphoma". This CME-certified initiative is intended for oncologists and hematologists, as well as other clinicians in the community setting who are actively involved in the diagnosis, treatment, and management of patients with non-Hodgkin’s lymphoma. A series of live CME-certified programs will be presented at selected hospitals throughout the US during 2012.

Program Description:

Treatment of relapsed/refractory non-Hodgkin’s lymphoma (NHL) is a rapidly evolving field. Community oncologists treat approximately 80% of cancer patients in the US each year, and they are constantly challenged to stay up to date with current management approaches, emerging data from ongoing studies of novel regimens, and key investigational agents for the treatment of relapsed/refractory NHL. Community oncologists who treat patients with NHL need access to new information, tools, and insights, which they can integrate into their practices to improve patient outcomes.

This educational activity is designed to meet that need and update community oncologists on recent advances in the management of relapsed/refractory NHL to ensure optimal patient outcomes.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement:

The Potomac Center for Medical Education designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email contact@potomacme.org.

Related Online Offerings

Back to Top

A calendar of live events, as well as additional CME-certified online programming for this and other Oncology Exchange programming, can be found at: www.medscape.org/viewcollection/32391.

Live Program Materials for Speakers and Administrators

Back to Top

I. Administrator Material

II. Speaker Material

Audio Orientation

Thank you for joining us as an expert speaker for the 2012 Visiting Professor series, "Oncology Exchange: Emerging Agents in Relapsed/Refractory Non-Hodgkin’s Lymphoma." This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions. During the audio lecture, the following key topics will be discussed:

  • Review the current approaches for the treatment of relapsed/refractory NHL
  • Compare the various available treatments and choose the optimal treatment based on patient characteristics and recently presented data from ongoing clinical studies in relapsed/refractory NHL
  • Identify key investigational agents from ongoing clinical studies in relapsed/refractory NHL

Transcript of Speaker Orientation Download (PDF)

Audio download of Speaker Orientation

Audio Download

CME-certified Program Slides

This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PowerPoint)

Steering Committee and Speaker Biographies

Back to Top

John P. Leonard, MDJohn P. Leonard, MD
Richard T. Silver Distinguished Professor of Hematology and
Medical Oncology
Vice Chairman and Associate Director for Clinical Research
Weill Cornell Cancer Center, Weill Cornell Medical College
Attending Physician, New York Presbyterian Hospital
New York, NY


John P. Leonard, MD is the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology and Professor of Medicine at the Weill Cornell Medical College. He also serves as Clinical Director of the New York – Cornell Center for Lymphoma and Myeloma, and as an Attending Physician at the New York Presbyterian Hospital. Dr. Leonard is Vice Chairman for Clinical Research in the Department of Medicine at Weill Cornell Medical College, and Associate Director for Clinical Research of the Weill Cornell Cancer Center.

An expert in hematology and oncology, Dr. Leonard’s research has been published in numerous medical journals, and he has served as a member of the editorial boards of Blood and the Journal of Clinical Oncology. He is the non-Hodgkin’s lymphoma working group leader for the Lymphoma Committee of the Cancer and Leukemia Group B (CALGB), a multicenter cooperative group of the National Cancer Institute. Dr. Leonard is an elected member of the American Board of Internal Medicine subspecialty board for hematology, and he has also been elected to membership in the American Society of Clinical Investigation. He is Chair-elect of the Scientific Advisory Board of the Lymphoma Research Foundation.

Dr. Leonard’s primary research interest is in the development of novel therapeutic strategies for the treatment of lymphoma and related hematologic malignancies, and he has lectured at major international meetings on these topics. Much of his work has involved the development of novel therapies for lymphoma, including radiolabeled and unlabeled monoclonal antibodies, other immune-based treatments, and other innovative approaches. He also has studied prognostic, imaging, and survivorship issues for lymphoma patients. Dr. Leonard performed his undergraduate work at Johns Hopkins University and received his medical degree at the University of Virginia School of Medicine in Charlottesville, VA. He completed his residency in medicine at the New York Hospital – Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York, NY. He completed a fellowship in hematology and oncology at Cornell, and served as the Chief Medical Resident at the New York Hospital – Cornell Medical Center.


Julie Vose, MD, MBAJulie Vose, MD, MBA
Neumann M. and Mildred E. Harris Professor
Chief, Division of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, NE


Julie Vose, MD, MBA is the Neumann M. and Mildred E. Harris Professor and Chief in the Division of Hematology/Oncology at the University of Nebraska Medical Center in Omaha, NE. Dr. Vose received her medical degree, completed her residency in internal medicine, served as Chief Resident, and completed a fellowship in hematology/oncology at the University of Nebraska Medical Center. She also completed a lymphoma vaccine therapy sabbatical in Dr. Ronald Levy’s lab at Stanford University. She recently completed an MBA in health administration through the University of Colorado Business School.

Dr. Vose has focused her career on translational research for improvement in the therapy of non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL) by developing a focused translational research program evaluating novel therapies such as radiolabeled monoclonal antibodies, idiotype vaccine therapies, pathway-directed agents, and stem cell transplantation. Dr. Vose has been recognized for her NHL research on a national and international level through research awards and invited lectureships worldwide. In addition, her funding record and publications in NHL therapy and transplantation research have added substantially to the research and knowledge base for the therapy of lymphoma. She is currently the Co-chair for the National Cancer Institute Lymphoma Sub-committee and a member of the FDA Oncologic Drug Advisory Committee.

Back to Top
Supported by an unrestricted educational grant from Genentech   
Jointly sponsored by  and
©2012 PCME